As of 2024-07-27, the EV/EBITDA ratio of Blueprint Medicines Corp (BPMC) is -16.65. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BPMC's latest enterprise value is 7,151.40 mil USD. BPMC's TTM EBITDA according to its financial statements is -429.56 mil USD. Dividing these 2 quantities gives us the above BPMC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.3x - 17.5x | 14.4x |
| Forward P/E multiples | 16.6x - 24.3x | 19.1x |
| Fair Price | (115.89) - (121.78) | (117.09) |
| Upside | -203.3% - -208.6% | -204.4% |
| Date | EV/EBITDA |
| 2024-07-26 | -16.65 |
| 2024-07-25 | -16.87 |
| 2024-07-24 | -17.05 |
| 2024-07-23 | -17.34 |
| 2024-07-22 | -17.32 |
| 2024-07-19 | -17.05 |
| 2024-07-18 | -16.83 |
| 2024-07-17 | -16.96 |
| 2024-07-16 | -17.86 |
| 2024-07-15 | -17.72 |
| 2024-07-12 | -17.46 |
| 2024-07-11 | -17.46 |
| 2024-07-10 | -17.20 |
| 2024-07-09 | -17.09 |
| 2024-07-08 | -17.25 |
| 2024-07-05 | -16.58 |
| 2024-07-03 | -16.19 |
| 2024-07-02 | -16.38 |
| 2024-07-01 | -16.21 |
| 2024-06-28 | -16.01 |
| 2024-06-27 | -16.11 |
| 2024-06-26 | -15.44 |
| 2024-06-25 | -15.83 |
| 2024-06-24 | -15.76 |
| 2024-06-21 | -15.49 |
| 2024-06-20 | -15.63 |
| 2024-06-18 | -15.85 |
| 2024-06-17 | -15.44 |
| 2024-06-14 | -15.68 |
| 2024-06-13 | -15.80 |
| 2024-06-12 | -15.77 |
| 2024-06-11 | -15.66 |
| 2024-06-10 | -15.46 |
| 2024-06-07 | -15.36 |
| 2024-06-06 | -15.52 |
| 2024-06-05 | -15.72 |
| 2024-06-04 | -15.15 |
| 2024-06-03 | -15.58 |
| 2024-05-31 | -15.68 |
| 2024-05-30 | -15.80 |
| 2024-05-29 | -14.95 |
| 2024-05-28 | -15.22 |
| 2024-05-24 | -15.28 |
| 2024-05-23 | -15.22 |
| 2024-05-22 | -15.27 |
| 2024-05-21 | -15.40 |
| 2024-05-20 | -15.49 |
| 2024-05-17 | -15.59 |
| 2024-05-16 | -15.84 |
| 2024-05-15 | -15.86 |